PT3027651T - Anticorpos anti-fgfr2iiib não fucosilados - Google Patents
Anticorpos anti-fgfr2iiib não fucosiladosInfo
- Publication number
- PT3027651T PT3027651T PT14752705T PT14752705T PT3027651T PT 3027651 T PT3027651 T PT 3027651T PT 14752705 T PT14752705 T PT 14752705T PT 14752705 T PT14752705 T PT 14752705T PT 3027651 T PT3027651 T PT 3027651T
- Authority
- PT
- Portugal
- Prior art keywords
- afucosylated anti
- fgfr2iiib antibodies
- fgfr2iiib
- antibodies
- afucosylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861198P | 2013-08-01 | 2013-08-01 | |
| US201361901732P | 2013-11-08 | 2013-11-08 | |
| US201461933632P | 2014-01-30 | 2014-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3027651T true PT3027651T (pt) | 2019-05-31 |
Family
ID=51358085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT14752705T PT3027651T (pt) | 2013-08-01 | 2014-07-31 | Anticorpos anti-fgfr2iiib não fucosilados |
| PT191511476T PT3708583T (pt) | 2013-08-01 | 2014-07-31 | Anticorpos anti-fgfr2iiib afucosilados |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT191511476T PT3708583T (pt) | 2013-08-01 | 2014-07-31 | Anticorpos anti-fgfr2iiib afucosilados |
Country Status (30)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552742A1 (en) | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| CA2926306C (en) * | 2013-11-05 | 2022-12-06 | F. Hoffmann-La Roche Ag | A method for determining the total amount and/or concentration of an analyte in a sample |
| JPWO2016171107A1 (ja) | 2015-04-20 | 2018-03-22 | 第一三共株式会社 | Ｆｇｆｒ２の検出 |
| CN116327924A (zh) * | 2015-11-23 | 2023-06-27 | 戊瑞治疗有限公司 | 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合 |
| PT3624837T (pt) * | 2017-05-16 | 2025-10-01 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro |
| CA3059472A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfr2 for cancer immunotherapy |
| CA3070774A1 (en) | 2017-08-25 | 2019-02-28 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| BR112020016990A2 (pt) | 2018-02-21 | 2021-02-23 | Five Prime Therapeutics, Inc. | regimes de dosagem de anticorpos contra b7-h4 |
| CA3091174A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| EA202091810A1 (ru) | 2018-03-02 | 2021-01-29 | Файв Прайм Терапьютикс, Инк. | Антитела к b7-h4 и способы их применения |
| SG11202102875YA (en) * | 2018-10-05 | 2021-04-29 | Five Prime Therapeutics Inc | Anti-fgfr2 antibody formulations |
| BR112021007134A2 (pt) | 2018-10-15 | 2021-08-10 | Five Prime Therapeutics, Inc. | terapia combinada para câncer |
| CA3160812A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| JP7685999B2 (ja) * | 2019-12-24 | 2025-05-30 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | 新規抗ＦＧＦＲ２ｂ抗体 |
| EP4081539A4 (en) * | 2019-12-24 | 2024-02-21 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| KR20220151195A (ko) | 2020-03-06 | 2022-11-14 | 오엔에이 테라퓨틱스 에스.엘. | 항-cd36 항체 및 암을 치료하기 위한 이의 용도 |
| CN116406379A (zh) * | 2020-10-22 | 2023-07-07 | 瑞泽恩制药公司 | 抗fgfr2抗体和其使用方法 |
| EP4273166A4 (en) * | 2020-12-29 | 2025-04-16 | Shenzhen Forward Pharmaceuticals Co., Limited | ANTI-FGFR2 ANTIBODIES AND USE THEREOF |
| IL309934A (en) | 2021-07-30 | 2024-03-01 | Ona Therapeutics S L | Anti-cd36 antibodies and their use to treat cancer |
| EP4414387A4 (en) * | 2021-10-08 | 2025-10-29 | Shenzhen Forward Pharmaceuticals Co Ltd | ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE |
| TW202342527A (zh) | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
| AU2023350283A1 (en) * | 2022-09-30 | 2025-05-22 | 3H Pharmaceuticals Co., Ltd. | Anti-fgfr2b antibodies and uses thereof |
| CN117917435A (zh) * | 2022-10-21 | 2024-04-23 | 北京天广实生物技术股份有限公司 | 结合fgfr2b的抗体及其用途 |
| WO2024140834A1 (en) * | 2022-12-28 | 2024-07-04 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-fgfr2b antibody and uses thereof |
| TW202442685A (zh) * | 2023-04-28 | 2024-11-01 | 大陸商武漢人福創新藥物研發中心有限公司 | 抗FGFR2b單抗 |
| WO2025103358A1 (en) * | 2023-11-14 | 2025-05-22 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-fgfr2b immunoconjugates and their use in the treatment of cancer |
| WO2025130860A1 (zh) * | 2023-12-18 | 2025-06-26 | 山东先声生物制药有限公司 | 抗FGFR2b抗体及其应用 |
| WO2025232811A1 (zh) * | 2024-05-09 | 2025-11-13 | 正大天晴药业集团股份有限公司 | 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| ES2133271T3 (es) | 1989-07-06 | 1999-09-16 | Univ California | Receptores para factores de crecimiento de fibroblastos. |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| AU3494397A (en) | 1996-06-18 | 1998-01-07 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fibroblast growth factor receptor activating gene i and related compositions and methods |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN1308347C (zh) | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| JP2001302699A (ja) | 2000-04-17 | 2001-10-31 | Nichirei Corp | ヒトｋｇｆｒに対する抗体 |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
| CN101357943A (zh) * | 2001-10-25 | 2009-02-04 | 杰南技术公司 | 糖蛋白组合物 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CN100531796C (zh) | 2002-01-31 | 2009-08-26 | 马普科技促进协会 | Fgfr激动剂 |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING ANTIBODY COMPOSITION |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| KR100493460B1 (ko) | 2002-08-29 | 2005-06-07 | 재단법인서울대학교산학협력재단 | 암 세포에서 발현되는 ｆｇｆｒ2 이성체 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| RU2337107C2 (ru) * | 2003-05-02 | 2008-10-27 | Ксенкор, Инк. | ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| US20070274981A1 (en) * | 2003-10-16 | 2007-11-29 | Imclone Systems Incorporation | Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof |
| NZ547279A (en) | 2003-10-22 | 2008-04-30 | Keck Graduate Inst | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| EP1697420A2 (en) | 2003-12-19 | 2006-09-06 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| WO2005115363A2 (en) | 2004-05-25 | 2005-12-08 | Yale University | Method for treating skeletal disorders resulting from fgfr malfunction |
| DE602006011574D1 (de) | 2005-01-27 | 2010-02-25 | Five Prime Therapeutics Inc | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
| US8207303B2 (en) * | 2005-02-18 | 2012-06-26 | Medarex, Inc. | Monoclonal antibodies against CD30 lacking in fucosyl residues |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| EP2041575A2 (en) | 2006-03-31 | 2009-04-01 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
| WO2007134210A2 (en) | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| WO2007146847A2 (en) * | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| AR062223A1 (es) * | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| HRP20160082T1 (hr) | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| US8394927B2 (en) | 2006-11-03 | 2013-03-12 | U3 Pharma Gmbh | FGFR4 antibodies |
| CL2007003411A1 (es) | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| TW200833711A (en) | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
| WO2008090959A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | エフェクター活性が増強された遺伝子組換え抗体組成物 |
| CA2680046A1 (en) | 2007-03-23 | 2008-10-02 | The Translational Genomics Research Institute | Methods of diagnosing, classifying and treating endometrial cancer and precancer |
| CA2682382A1 (en) * | 2007-03-28 | 2008-10-09 | Biogen Idec Inc. | Non-fucosylated antibodies |
| US20110091473A1 (en) | 2007-10-22 | 2011-04-21 | Genmab A/S | Novel antibody therapies |
| US20110059091A1 (en) | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
| US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| JP5212466B2 (ja) | 2008-03-26 | 2013-06-19 | 日本電気株式会社 | 無線リソースの制御方法、無線局装置、無線局制御プログラム、及び無線通信システム |
| WO2009151448A1 (en) * | 2008-06-10 | 2009-12-17 | University Of Southern California | Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| LT2842573T (lt) * | 2008-11-07 | 2017-12-11 | Galaxy Biotech, Llc | Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2 |
| WO2011025814A1 (en) | 2009-08-25 | 2011-03-03 | National Jewish Health | Methods and compositions for treatment of lung injury |
| CN102666874B (zh) * | 2009-10-07 | 2016-06-01 | 宏观基因有限公司 | 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法 |
| JP2013508292A (ja) * | 2009-10-14 | 2013-03-07 | カロバイオス ファーマシューティカルズ インコーポレイティッド | ＥｐｈＡ３に対する抗体 |
| US20120328599A1 (en) | 2010-01-14 | 2012-12-27 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| WO2011115937A1 (en) | 2010-03-14 | 2011-09-22 | The Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| AU2011253101A1 (en) | 2010-05-11 | 2013-01-10 | Aveo Pharmaceuticals, Inc. | Anti-FGFR2 antibodies |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CN103201287B (zh) | 2010-08-12 | 2016-04-13 | 艾托生物有限公司 | 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途 |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| EP3219731A1 (en) * | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| JP2015505850A (ja) | 2011-12-14 | 2015-02-26 | シアトル ジェネティックス， インコーポレイテッド | 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用 |
| US20150329621A1 (en) * | 2012-03-30 | 2015-11-19 | The Regents Of The University Of California | Anti-emp2 therapy reduces cancer stem cells |
| KR102115143B1 (ko) | 2012-04-09 | 2020-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 ｆｇｆｒ２ 항체 |
| US9254288B2 (en) | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US20150191791A1 (en) | 2012-07-05 | 2015-07-09 | Lsip, Llc | Fgfr2 fusion gene |
| WO2014089193A1 (en) | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| US10980804B2 (en) | 2013-01-18 | 2021-04-20 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| AU2014259956A1 (en) | 2013-05-01 | 2015-11-12 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| CN105658810B (zh) | 2013-06-13 | 2020-08-21 | 南澳大学 | 用于检测前列腺癌的方法 |
| PH12021552742A1 (en) | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20170175197A1 (en) | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN116327924A (zh) | 2015-11-23 | 2023-06-27 | 戊瑞治疗有限公司 | 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合 |
| PT3624837T (pt) | 2017-05-16 | 2025-10-01 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro |
-
2014
- 2014-07-31 PH PH1/2021/552742A patent/PH12021552742A1/en unknown
- 2014-07-31 CA CA2915665A patent/CA2915665C/en active Active
- 2014-07-31 SG SG11201600767UA patent/SG11201600767UA/en unknown
- 2014-07-31 KR KR1020167005003A patent/KR102516152B1/ko active Active
- 2014-07-31 PH PH1/2019/501393A patent/PH12019501393B1/en unknown
- 2014-07-31 TW TW103126289A patent/TWI633120B/zh active
- 2014-07-31 CN CN202010986598.1A patent/CN112225810B/zh active Active
- 2014-07-31 ME MEP-2019-142A patent/ME03476B/me unknown
- 2014-07-31 US US14/447,751 patent/US20150050273A1/en not_active Abandoned
- 2014-07-31 DK DK19151147.6T patent/DK3708583T3/da active
- 2014-07-31 KR KR1020237010509A patent/KR102825701B1/ko active Active
- 2014-07-31 HU HUE14752705A patent/HUE043815T2/hu unknown
- 2014-07-31 PE PE2021000044A patent/PE20210949A1/es unknown
- 2014-07-31 TW TW107125185A patent/TWI679021B/zh active
- 2014-07-31 RS RS20190588A patent/RS58719B1/sr unknown
- 2014-07-31 HU HUE19151147A patent/HUE058243T2/hu unknown
- 2014-07-31 JP JP2016531878A patent/JP6860342B2/ja active Active
- 2014-07-31 ES ES14752705T patent/ES2719103T3/es active Active
- 2014-07-31 RU RU2016106101A patent/RU2698061C2/ru active
- 2014-07-31 WO PCT/US2014/049008 patent/WO2015017600A1/en not_active Ceased
- 2014-07-31 ES ES19151147T patent/ES2913291T3/es active Active
- 2014-07-31 EP EP22151171.0A patent/EP4036118A1/en active Pending
- 2014-07-31 PE PE2016000119A patent/PE20160190A1/es unknown
- 2014-07-31 AU AU2014296174A patent/AU2014296174B2/en active Active
- 2014-07-31 HR HRP20190502TT patent/HRP20190502T1/hr unknown
- 2014-07-31 PT PT14752705T patent/PT3027651T/pt unknown
- 2014-07-31 LT LTEP14752705.5T patent/LT3027651T/lt unknown
- 2014-07-31 DK DK14752705.5T patent/DK3027651T3/en active
- 2014-07-31 EP EP19151147.6A patent/EP3708583B1/en active Active
- 2014-07-31 RU RU2019125027A patent/RU2740714C2/ru active
- 2014-07-31 LT LTEP19151147.6T patent/LT3708583T/lt unknown
- 2014-07-31 KR KR1020257020887A patent/KR20250099279A/ko active Pending
- 2014-07-31 SI SI201431949T patent/SI3708583T1/sl unknown
- 2014-07-31 PL PL19151147T patent/PL3708583T3/pl unknown
- 2014-07-31 PL PL14752705T patent/PL3027651T3/pl unknown
- 2014-07-31 MX MX2016001236A patent/MX374785B/es active IP Right Grant
- 2014-07-31 CN CN201480043427.8A patent/CN105452296B/zh active Active
- 2014-07-31 EP EP14752705.5A patent/EP3027651B1/en active Active
- 2014-07-31 NZ NZ715201A patent/NZ715201A/en unknown
- 2014-07-31 SI SI201431132T patent/SI3027651T1/sl unknown
- 2014-07-31 PT PT191511476T patent/PT3708583T/pt unknown
- 2014-07-31 MY MYPI2016000176A patent/MY184628A/en unknown
-
2015
- 2015-12-29 IL IL24340915A patent/IL243409B/en active IP Right Grant
-
2016
- 2016-01-15 ZA ZA2016/03218A patent/ZA201603218B/en unknown
- 2016-01-21 PH PH12016500137A patent/PH12016500137B1/en unknown
- 2016-01-28 CL CL2016000221A patent/CL2016000221A1/es unknown
- 2016-01-28 MX MX2020009223A patent/MX2020009223A/es unknown
- 2016-05-27 US US15/166,798 patent/US10172937B2/en active Active
-
2018
- 2018-08-10 CL CL2018002291A patent/CL2018002291A1/es unknown
- 2018-11-06 US US16/181,784 patent/US11235059B2/en active Active
-
2019
- 2019-04-05 CY CY20191100382T patent/CY1121517T1/el unknown
- 2019-07-17 AU AU2019206039A patent/AU2019206039B2/en active Active
- 2019-10-25 JP JP2019194319A patent/JP7183136B2/ja active Active
-
2021
- 2021-10-07 AU AU2021245169A patent/AU2021245169B2/en active Active
- 2021-12-17 US US17/554,423 patent/US12465636B2/en active Active
-
2022
- 2022-02-14 JP JP2022020496A patent/JP2022078080A/ja active Pending
- 2022-05-10 CY CY20221100324T patent/CY1125443T1/el unknown
- 2022-11-21 JP JP2022185432A patent/JP2023018049A/ja active Pending
-
2025
- 2025-01-17 US US19/030,119 patent/US20250269016A1/en active Pending
- 2025-04-03 JP JP2025061908A patent/JP2025118617A/ja active Pending
- 2025-05-15 AU AU2025203545A patent/AU2025203545A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201808451B (en) | Anti-fcrh5 antibodies | |
| ZA201603218B (en) | Afucosylated anti-fgfr2iiib antibodies | |
| GB201322583D0 (en) | Antibodies | |
| SG11201509361TA (en) | Novel antibodies | |
| ZA201601437B (en) | Antibodies | |
| HUE038414T2 (hu) | Összekapcsoló eszköz | |
| GB201308658D0 (en) | Antibodies | |
| GB201315486D0 (en) | Antibodies | |
| GB201300706D0 (en) | Antibody | |
| IL245488A0 (en) | Anti- ccl17 antibodies | |
| GB201303507D0 (en) | Assays | |
| GB201312226D0 (en) | Improved antibodies | |
| HK40091931A (zh) | 抗fcrh5抗体 | |
| HK40044506B (zh) | 无岩藻糖基化抗fgfr2iiib抗体 | |
| GB201318283D0 (en) | Antibodies |